XML 62 R30.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Revenues (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Revenue from Contract with Customer [Abstract] |
Revenues by product | Revenue by product is summarized as follows:
|  | For the Three Months Ended September 30,
|  | 2022 |  | 2021
(In millions) |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |
TECFIDERA |  | $ | 92.5 |  |  | $ | 246.5 |  |  | $ | 339.0 |  |  | $ | 179.2 |  |  | $ | 319.4 |  |  | $ | 498.6 |
VUMERITY(1) |  | 127.9 |  |  | 9.9 |  |  | 137.8 |  |  | 120.7 |  |  | 0.2 |  |  | 120.9 |
Total Fumarate |  | 220.4 |  |  | 256.4 |  |  | 476.8 |  |  | 299.9 |  |  | 319.6 |  |  | 619.5 |
AVONEX |  | 174.8 |  |  | 80.3 |  |  | 255.1 |  |  | 213.2 |  |  | 88.1 |  |  | 301.3 |
PLEGRIDY |  | 39.7 |  |  | 41.2 |  |  | 80.9 |  |  | 39.2 |  |  | 47.0 |  |  | 86.2 |
Total Interferon |  | 214.5 |  |  | 121.5 |  |  | 336.0 |  |  | 252.4 |  |  | 135.1 |  |  | 387.5 |
TYSABRI |  | 273.0 |  |  | 232.5 |  |  | 505.5 |  |  | 281.1 |  |  | 241.7 |  |  | 522.8 |
FAMPYRA |  | — |  |  | 22.0 |  |  | 22.0 |  |  | — |  |  | 26.2 |  |  | 26.2 |
Subtotal: MS |  | 707.9 |  |  | 632.4 |  |  | 1,340.3 |  |  | 833.4 |  |  | 722.6 |  |  | 1,556.0 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA |  | 140.2 |  |  | 290.9 |  |  | 431.1 |  |  | 139.8 |  |  | 304.3 |  |  | 444.1 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |  |
BENEPALI |  | — |  |  | 110.2 |  |  | 110.2 |  |  | — |  |  | 120.8 |  |  | 120.8 |
IMRALDI |  | — |  |  | 57.7 |  |  | 57.7 |  |  | — |  |  | 57.4 |  |  | 57.4 |
FLIXABI |  | — |  |  | 19.0 |  |  | 19.0 |  |  | — |  |  | 24.6 |  |  | 24.6 |
BYOOVIZ(2) |  | 0.7 |  |  | — |  |  | 0.7 |  |  | — |  |  | — |  |  | — |
Subtotal: Biosimilars |  | 0.7 |  |  | 186.9 |  |  | 187.6 |  |  | — |  |  | 202.8 |  |  | 202.8 |
Other: |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM |  | — |  |  | 1.5 |  |  | 1.5 |  |  | — |  |  | 2.5 |  |  | 2.5 |
ADUHELM |  | 1.6 |  |  | — |  |  | 1.6 |  |  | 0.3 |  |  | — |  |  | 0.3 |
Total product revenue |  | $ | 850.4 |  |  | $ | 1,111.7 |  |  | $ | 1,962.1 |  |  | $ | 973.5 |  |  | $ | 1,232.2 |  |  | $ | 2,205.7 |
(1) VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021. (2) BYOOVIZ launched in the United States (U.S.) in June 2022 and became commercially available during the third quarter of 2022.
|  | For the Nine Months Ended September 30,
|  | 2022 |  | 2021
(In millions) |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |
TECFIDERA |  | $ | 330.3 |  |  | $ | 816.5 |  |  | $ | 1,146.8 |  |  | $ | 520.1 |  |  | $ | 945.3 |  |  | $ | 1,465.4 |
VUMERITY(1) |  | 383.0 |  |  | 19.6 |  |  | 402.6 |  |  | 285.0 |  |  | 0.5 |  |  | 285.5 |
Total Fumarate |  | 713.3 |  |  | 836.1 |  |  | 1,549.4 |  |  | 805.1 |  |  | 945.8 |  |  | 1,750.9 |
AVONEX |  | 493.8 |  |  | 249.6 |  |  | 743.4 |  |  | 636.4 |  |  | 286.9 |  |  | 923.3 |
PLEGRIDY |  | 114.2 |  |  | 138.2 |  |  | 252.4 |  |  | 115.2 |  |  | 149.9 |  |  | 265.1 |
Total Interferon |  | 608.0 |  |  | 387.8 |  |  | 995.8 |  |  | 751.6 |  |  | 436.8 |  |  | 1,188.4 |
TYSABRI |  | 849.4 |  |  | 693.1 |  |  | 1,542.5 |  |  | 854.2 |  |  | 696.2 |  |  | 1,550.4 |
FAMPYRA |  | — |  |  | 73.7 |  |  | 73.7 |  |  | — |  |  | 78.8 |  |  | 78.8 |
Subtotal: MS |  | 2,170.7 |  |  | 1,990.7 |  |  | 4,161.4 |  |  | 2,410.9 |  |  | 2,157.6 |  |  | 4,568.5 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA |  | 443.3 |  |  | 891.4 |  |  | 1,334.7 |  |  | 437.8 |  |  | 1,026.6 |  |  | 1,464.4 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |  |
BENEPALI |  | — |  |  | 340.7 |  |  | 340.7 |  |  | — |  |  | 363.9 |  |  | 363.9 |
IMRALDI |  | — |  |  | 172.4 |  |  | 172.4 |  |  | — |  |  | 170.9 |  |  | 170.9 |
FLIXABI |  | — |  |  | 62.0 |  |  | 62.0 |  |  | — |  |  | 75.4 |  |  | 75.4 |
BYOOVIZ(2) |  | 1.2 |  |  | — |  |  | 1.2 |  |  | — |  |  | — |  |  | — |
Subtotal: Biosimilars |  | 1.2 |  |  | 575.1 |  |  | 576.3 |  |  | — |  |  | 610.2 |  |  | 610.2 |
Other: |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM |  | — |  |  | 6.4 |  |  | 6.4 |  |  | — |  |  | 8.3 |  |  | 8.3 |
ADUHELM |  | 4.5 |  |  | — |  |  | 4.5 |  |  | 2.0 |  |  | — |  |  | 2.0 |
Total product revenue |  | $ | 2,619.7 |  |  | $ | 3,463.6 |  |  | $ | 6,083.3 |  |  | $ | 2,850.7 |  |  | $ | 3,802.7 |  |  | $ | 6,653.4 |
(1) VUMERITY became commercially available in the E.U. during the fourth quarter of 2021. (2) BYOOVIZ launched in the U.S. in June 2022 and became commercially available during the third quarter of 2022.
Analysis of change In reserves | An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) |  | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, December 31, 2021 |  | $ | 137.7 |  |  | $ | 759.6 |  |  | $ | 38.0 |  |  | $ | 935.3 |
Current provisions relating to sales in current year |  | 499.3 |  |  | 1,993.6 |  |  | 8.5 |  |  | 2,501.4 |
Adjustments relating to prior years |  | (2.5) |  |  | (18.4) |  |  | (7.7) |  |  | (28.6) |
Payments/credits relating to sales in current year |  | (379.6) |  |  | (1,442.0) |  |  | — |  |  | (1,821.6) |
Payments/credits relating to sales in prior years |  | (124.5) |  |  | (463.7) |  |  | (14.4) |  |  | (602.6) |
Balance, September 30, 2022 |  | $ | 130.4 |  |  | $ | 829.1 |  |  | $ | 24.4 |  |  | $ | 983.9 |
Total reserves included in consolidated balance sheets | The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) |  | As of September 30, 2022 |  | As of December 31, 2021
Reduction of accounts receivable |  | $ | 129.4 |  |  | $ | 133.2 |
Component of accrued expense and other |  | 854.5 |  |  | 802.1 |
Total revenue-related reserves |  | $ | 983.9 |  |  | $ | 935.3 |
Revenues from anti-CD20 therapeutic programs | Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
|  | For the Three Months Ended September 30, |  | For the Nine Months Ended September 30,
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA |  | $ | 131.1 |  |  | $ | 145.8 |  |  | $ | 414.2 |  |  | $ | 498.7 |
OCREVUS and other revenue from anti-CD20 therapeutic programs |  | 285.8 |  |  | 269.6 |  |  | 838.4 |  |  | 745.7 |
Total revenue from anti-CD20 therapeutic programs |  | $ | 416.9 |  |  | $ | 415.4 |  |  | $ | 1,252.6 |  |  | $ | 1,244.4 |
Other revenues | Other revenue is summarized as follows:
|  | For the Three Months Ended September 30, |  | For the Nine Months Ended September 30,
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Revenue from collaborative and other relationships: |  |  |  |  |  |  |  |
Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis |  | $ | 6.5 |  |  | $ | 6.3 |  |  | $ | 20.9 |  |  | $ | 15.7 |
Other royalty and corporate revenue: |  |  |  |  |  |  |  |
Royalty |  | 8.8 |  |  | 7.7 |  |  | 29.7 |  |  | 20.3 |
Other corporate |  | 114.2 |  |  | 143.8 |  |  | 242.9 |  |  | 314.1 |
Total other revenue |  | $ | 129.5 |  |  | $ | 157.8 |  |  | $ | 293.5 |  |  | $ | 350.1 |

X
- Definition Analysis of amount of and change in product revenue reserves. + References No definition available. + Details
Name: | biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other revenues [Table Text Block] + References No definition available. + Details
Name: | biib_OtherrevenuesTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of total product revenue reserves included in consolidated balance sheets. + References No definition available. + Details
Name: | biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration